# Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Source: https://onco.cc/trials/nct04632758/  
OnCo record `nct04632758` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Iruplinalkib and Crizotinib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.

## Summary

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients is a phase 3 interventional study registered as NCT04632758 by Qilu Pharmaceutical Co., Ltd., with 292 participants planned, started 2019-06-01 and due to reach its primary completion in 2024-12-01. Interventions recorded: WX-0593 Tablets, crizotinib. Conditions recorded: Non-small Cell Lung Cancer.

Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04632758
- Phase: 3
- Setting: An Open-label, Randomized, Multicenter Phase 3 Study Comparing WX-0593 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 292

## Sources

- ClinicalTrials.gov NCT04632758: https://clinicaltrials.gov/study/NCT04632758

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Iruplinalkib](https://onco.cc/drugs/iruplinalkib/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct04632758.json